TuHURA Biosciences (NASDAQ:HURA) Stock Breaks Below 200-Day Moving Average – Here’s What Happened

TuHURA Biosciences, Inc. (NASDAQ:HURA)’s share price passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $1.96 and traded as low as $1.85. TuHURA Biosciences shares last traded at $1.93, with a volume of 519,359 shares changing hands.

Analysts Set New Price Targets

HURA has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday. Citizens Jmp reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

TuHURA Biosciences Stock Down 6.3%

The stock’s 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.96. The firm has a market cap of $123.00 million, a P/E ratio of -3.57 and a beta of -0.21. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, research analysts forecast that TuHURA Biosciences, Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new stake in shares of TuHURA Biosciences during the second quarter valued at approximately $33,000. Merck & Co. Inc. purchased a new position in TuHURA Biosciences in the 2nd quarter worth approximately $45,501. Sanctuary Advisors LLC bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $49,000. Deutsche Bank AG bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $52,000. Finally, Hsbc Holdings PLC bought a new position in TuHURA Biosciences in the 2nd quarter valued at approximately $69,000. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.